Business Context and Reporting Period
Company: Omeros Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: February 20, 2025
Principal Executive Offices: West Seattle, WA
Trading Symbol: OMER (Nasdaq Stock Market LLC)
This filing reports "Other Events" (Item 8.01) regarding the announcement of statistical analysis results for an expanded access program for the company's investigational drug, narsoplimab.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific corporate event and does not contain financial statements or quarterly results.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The material event is the release of statistical data concerning the expanded access program for narsoplimab, a first-in-class monoclonal antibody designed to inhibit the lectin pathway of complement for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release (Exhibit 99.1) detailing the statistical analysis results. No specific forward-looking guidance, financial outlook, or risk factors are explicitly detailed within the text of this 8-K summary.
Investor Verification Checklist
- Review the full text of the press release filed as Exhibit 99.1 to understand the specific statistical outcomes of the narsoplimab expanded access program.
- Verify the clinical implications of the reported data for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy.
- Check subsequent filings for any updates on regulatory strategy or trial design changes resulting from these statistical results.